Every Form 4 that Cartesian Therapeutics, Inc. (RNAC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RNAC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RNAC filings page.
Cartesian Therapeutics, Inc. insider reporting shows a trust-related conversion of preferred stock into common stock. On April 2, 2026, Seven One Eight Three Four Irrevocable Trust elected to convert a portion of its Series A Non-Voting Convertible Preferred Stock into 758,001 shares of common stock at a stated conversion price of $0.0000 per share, all held indirectly with Elizabeth Hoge acting as trustee.
Following the conversion, the Trust holds 5,313,261 shares of common stock and 33,662.224 shares of Series A Non-Voting Convertible Preferred Stock, with the remaining preferred shares subject to a beneficial ownership limitation. A separate indirect holding reflects 506,999 shares of common stock held by Hoge's spouse. Footnotes state these securities stem from merger consideration and a private placement completed in November 2023.
Cartesian Therapeutics, Inc. insider filing shows a trust converting preferred stock into common shares. On April 2, 2026, a trust for the benefit of Murat Kalayoglu’s spouse and children exercised 22,740.03 shares of Series A Non-Voting Convertible Preferred Stock to acquire 758,001 shares of common stock at a conversion price of $0.00 per share.
After the transaction, the trust held 33,662.224 shares of the preferred stock and 5,313,261 shares of common stock indirectly. Murat Kalayoglu also held 506,999 shares of common stock directly. The filing reflects a derivative exercise and conversion, not an open-market purchase or sale.
Cartesian Therapeutics director Michael Singer reported a bona fide gift of 6,555 shares of Common Stock on March 13, 2026. The gift was made at no stated price and is classified as a non-market disposition rather than a sale.
After the gift, Singer directly holds 49,578 shares. He also reports additional indirect holdings in Cartesian Therapeutics through several trusts, a spouse account, and custodial accounts for his children under UTMA.
Cartesian Therapeutics President and CEO Carsten Brunn reported a sale of company common stock. On 01/06/2026, he sold 23,766 shares of Cartesian Therapeutics, Inc. (RNAC) common stock at a price of $6.8197 per share.
According to the footnote, these shares were sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. After this transaction, Brunn directly beneficially owned 323,530 shares of Cartesian Therapeutics common stock.
Cartesian Therapeutics Chief Medical Officer Milos Miljkovic reported a small sale of company stock tied to equity compensation taxes. On 01/06/2026, he sold 3,573 shares of Cartesian Therapeutics, Inc. common stock at a price of $6.8197 per share. According to the footnote, the shares were sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees, rather than as a discretionary open-market sale. After this transaction, he continued to beneficially own 58,820 shares of common stock in direct ownership.
Cartesian Therapeutics, Inc. reported an insider transaction by its Chief Financial Officer, Blaine Davis. On 01/06/2026, Davis sold 10,591 shares of the company’s common stock at an average price of $6.8197 per share. According to the disclosure, these shares were sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees, indicating a tax-related sale rather than a discretionary open-market reduction in holdings. Following this transaction, Davis beneficially owned 121,220 shares of Cartesian Therapeutics common stock directly.
Cartesian Therapeutics director Patrick Zenner reported new equity awards. On January 2, 2026, he acquired 2,600 shares of common stock at a price of $0, representing restricted stock units that will vest in full on January 2, 2027. On the same date, he was granted a stock option for 7,800 shares of common stock at an exercise price of $6.76 per share, first exercisable on January 2, 2027 and expiring on January 1, 2036. After these transactions, he directly beneficially owned 12,974 shares of common stock and 7,800 stock options.
Cartesian Therapeutics Chief Operations Officer Emily English reported new equity awards in the company’s stock. On January 2, 2026, she received 24,000 shares of common stock at a price of $0, bringing her directly owned common stock holdings to 94,226 shares.
On the same date, she was granted an employee stock option for 71,000 shares of common stock at an exercise price of $6.76 per share, expiring on January 1, 2036. The restricted stock units vest 25% on January 2, 2027, with the rest vesting in three equal annual installments through January 2, 2030, while the option vests 25% on January 2, 2027, and the remaining 75% in 36 equal monthly installments thereafter.
Cartesian Therapeutics director Michael Singer reported new equity awards from the company, including 7,800 stock options and 2,600 restricted stock units granted on January 2, 2026. The stock options give him the right to buy 7,800 shares of common stock at $6.76 per share, become exercisable on January 2, 2027, and expire on January 1, 2036. The restricted stock units represent contingent rights to receive 2,600 shares of common stock that will vest in full on January 2, 2027. Following these awards, he directly holds 56,133 common shares and has additional indirect holdings through several trusts, his spouse, and custodial accounts for his children.
Cartesian Therapeutics, Inc. director and 10% owner Timothy A. Springer reported new equity awards. On January 2, 2026, he received 2,600 shares of common stock at a price of $0 through restricted stock units that will vest in full on January 2, 2027. He was also granted a stock option for 7,800 shares of common stock at an exercise price of $6.76 per share, exercisable starting January 2, 2027 and expiring January 1, 2036. Following these awards, he directly beneficially owned 8,646,285 shares of common stock, with additional indirect holdings of 330,695 shares by his wife and 656,513 shares held by TAS Partners LLC, for which he is managing member and disclaims beneficial ownership except to the extent of any pecuniary interest.
Cartesian Therapeutics director and 10% owner Murat Kalayoglu reported new equity awards. On January 2, 2026, he received 2,600 shares of common stock in the form of restricted stock units, each representing one share that will vest in full on January 2, 2027. He also was granted a stock option for 7,800 shares of common stock at an exercise price of $6.76 per share, exercisable starting January 2, 2027 and expiring January 1, 2036.
After these transactions, he directly beneficially owned 511,577 shares of Cartesian Therapeutics common stock and held an additional 4,555,260 shares indirectly through a trust for the benefit of his spouse and children.
Cartesian Therapeutics, Inc. reported that a director received new equity awards in the form of common stock and stock options. On 12/16/2025, the director was granted 5,800 shares of common stock at a price of $0, recorded as an acquisition of non-derivative securities. Following this grant, the director beneficially owned 5,800 common shares directly.
The filing also discloses a derivative award of a stock option for 17,200 shares of common stock with an exercise price of $8.29, granted on 12/16/2025 and expiring on 12/15/2035. The 5,800-share restricted stock unit grant will vest in three equal annual installments so that all underlying shares are fully vested on December 16, 2028. The 17,200-share stock option will vest in 36 equal monthly installments and is also scheduled to be fully vested on December 16, 2028.
Cartesian Therapeutics, Inc. (RNAC) reported an insider transaction by a director on 11/18/2025. The director gifted 20,000 shares of common stock, reported with transaction code G at a stated price of $0 per share, which is typical for a charitable or family transfer. After this transaction, the director held 53,533 shares directly. Additional shares are reported as indirectly held, including 383,796 shares in a trust for the benefit of the director’s spouse and children, as well as other trusts and custodial accounts for family members.
Cartesian Therapeutics (RNAC) reported a Form 4 for its Chief Accounting Officer, June Ann Seymour, documenting an equity award. On 10/27/2025, Seymour received an employee stock option to purchase 50,000 shares at an exercise price of $8.85 per share, expiring on 10/27/2035.
The option vests as to 25% on 10/27/2026, with the remaining underlying shares vesting in three equal annual installments so that all shares are fully vested on 10/27/2029. The filing lists ownership of the derivative security as Direct (D) with 50,000 derivative securities beneficially owned following the reported transaction.